There are currently few effective treatments available for advanced or metastatic uveal melanoma, including surgery to remove the cancer, radiotherapy or chemotherapy. IMCgp100 is a drug under development that would enable the body’s own immune system to recognise and specifically target and kill cancer cells. IMCgp100 is given by intravenous infusion and is currently being studied in patients with advanced/ metastatic uveal melanoma. It will offer a new treatment option if licenced.
IMCgp100 for the Treatment of Advanced or Metastatic Uveal Melanoma
Interventions:
IMCgp100 (Tebentafusp)
Indications:
Uveal melanoma
Therapeutic Areas:
Oncology
Year:
2017